Samsung Biologics Co., Ltd. (SSBIOLOGICS) financials
KSC · Healthcare · Biotechnology · 5,455 employees · CEO John Chongbo Rim
- Price
- $1,001 -0.1%
- Market cap
- $48.5B
- Enterprise value
- ₩65.5T Data as of 2026-11-21
- Last report
- Q3 '26 filed 2026-09-30
- Next report
- 2027-01-27 EPS est. ₩11,137.25
Valuation & key figures
- Market cap
- $48.5B Updated 46m ago
- Revenue
- ₩4.38T Trailing 12 months
- Revenue growth
- – Next fiscal year
- Profit margin
- 41.1% Net income / revenue, TTM
- P/E
- 34.9×
- P/S
- 14.9× Price / sales, TTM
- EV / EBITDA
- 25.9× TTM
- Free cash flow
- ₩1.45T Trailing 12 months
- Net income
- ₩1.8T Trailing 12 months
- Revenue estimate
- – Next fiscal year
- Earnings
- 2027-01-27 Revenue est. $1.12B · Updated 46m ago
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-10-21): revenue beat by 9.7%, EPS missed by 13.8%Revenue ₩1.49T vs ₩1.36T expected (+9.7%); EPS ₩8,448.73 vs ₩9,799.29 (-13.8%).
- Revenue growth slowing: -10.2% year on yearQ3 '26 revenue ₩1.49T, against an average of -9.1% over the four quarters before.
- Operating margin 43.4% (TTM), +6.7 pp on a year agoOperating income grew -5.9% while revenue grew -20.5%.
- 13.7% of pre-tax profit is non-operatingPre-tax income ₩2.2T vs operating income ₩1.9T (TTM). Gains on equity stakes and other one-off items lift net income and EPS - operating income is the cleaner measure of the business.
- Capex 17.6% of revenue (a year ago 26.7%)₩769B invested in the last 4 quarters (-47.7% on a year earlier). Free cash flow ₩1.45T = 80.7% of net income.
- Returned ₩92B to shareholders = 6.3% of free cash flowBuybacks ₩92B (a year earlier ₩0), dividends ₩0, stock-based pay ₩0 (TTM).
- Diluted share count up 0.7% in a year46.6M diluted shares in Q3 '26, 46.3M a year earlier.
- Net cash ₩1.28TCash + short-term investments ₩2.32T, debt incl. leases ₩1.04T; a year ago net cash ₩708B.
Last quarter: Q3 '26
Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q3 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | ₩1.49T | ₩1.66T | -10.2% |
| Gross margin | 100.0% | 61.1% | +38.9 pp |
| Operating income | ₩640B | ₩729B | -12.2% |
| Operating margin | 43.0% | 43.9% | -0.9 pp |
| Net income | ₩391B | ₩574B | -31.9% |
| Diluted EPS | ₩8,391.77 | ₩12,409.00 | -32.4% |
| Operating cash flow | ₩409B | ₩619B | -34.0% |
| Capex | ₩56.9B | ₩114B | -50.0% |
| Free cash flow | ₩352B | ₩505B | -30.4% |
| R&D | ₩0 | ₩107B | -100.0% |
| Stock-based compensation | ₩0 | ₩0 | – |
Reported vs consensus
2026-10-21| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | ₩1.49T | ₩1.36T | +9.7% |
| EPS (as estimated) | ₩8,448.73 | ₩9,799.29 | -13.8% |
From the report of 2026-10-21 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyMargins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- ₩2.22T
- Capex
- -₩769B
- Buybacks
- -₩92B
- Dividends
- ₩0
- Acquisitions
- -₩534B
- Net debt issued
- -₩157B
- Stock-based compensation
- ₩0
- Free cash flow
- ₩1.45T
- Returned to shareholders / FCF
- 6.3%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | 34.9× | 79.4× | 43.9× – 153.4× |
| EV / EBITDA | 25.9× | 44.5× | 28.5× – 83.5× |
| EV / Sales | 15.0× | 22.3× | 15.6× – 39.3× |
| Price / FCF | 44.8× | 559.2× 4 of 5 years | 91.6× – 1,805.4× |
| Price / Book | 7.3× | 8.2× | 5.7× – 12.1× |
| FCF yield | 2.2% | 0.5% | -0.1% – 1.1% |
| Return on invested capital | 13.8% | 8.5% | 5.4% – 17.8% |
| Return on equity | 22.2% | 11.9% | 7.9% – 23.9% |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings.
Data as of 2026-11-21 · Amounts in KRW as reported; price and market cap in USD.